Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZL1201 |
Synonyms | |
Therapy Description |
ZL1201 is a monoclonal anti-CD47 antibody that binds to the cell surface antigen CD47 and inhibits its interaction with signal regulatory protein alpha on phagocytic cells, and may lead to immune cell activation and tumor cell phagocytosis (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZL1201 | ZL 1201|ZL-1201 | CD47 Antibody 31 | ZL1201 is a monoclonal anti-CD47 antibody that binds to the cell surface antigen CD47 and inhibits its interaction with signal regulatory protein alpha on phagocytic cells, and may lead to immune cell activation and tumor cell phagocytosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04257617 | Phase I | ZL1201 | A Trial of ZL-1201 in Subjects With Advanced Cancer | Completed | USA | 1 |